LifeScience Biologics
From Capacity to Capability: The New Race to Lead ASEAN Biomanufacturing
ASEAN is entering a new phase of biopharmaceutical manufacturing, where simply building more capacity will no longer guarantee competitiveness. As ...
July 17, 2026 | Expert Insight
Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence
REPORTAGE / PLASMA SUPPLY THE CHAIR The chair reclines. That is the first thing you notice, walking into a plasma centre in a strip mall on...
July 17, 2026 | Analysis
Harbour BioMed, Kelun-Biotech Secure China IND Approval for Bispecific Antibody in Asthma
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, o...
July 17, 2026 | News
Evonik and evitria Simplify CHO-Based Protein Production with Ready-to-Use Expression Kit
New ready-to-use protein expression kit now available eviCHO Expression Kit simplifies transient protein expression workflows and enables faster, ...
July 17, 2026 | News
China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?
THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...
July 16, 2026 | Analysis
Kelun-Biotech’s Sac-TMT–Keytruda Combination Outperforms Standard First-Line Therapy in Phase III Lung Cancer Trial
As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-L...
July 16, 2026 | News
GEM Commits Up to $15.5M to Back Senhwa Biosciences’ Oncology Pipeline
GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc...
July 16, 2026 | News
Delonix Bioworks Doses First Participant in China Phase 1 Trial of Next-Generation MenB Vaccine DX-104
Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, announced that the first participant has bee...
July 15, 2026 | News
Leads Biolabs' Opamtistomig Receives China's Priority Review for Advanced Neuroendocrine Cancer
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Op...
July 14, 2026 | News
Pfizer and Astellas Expand FDA Approval of PADCEV Plus Keytruda Across All Muscle-Invasive Bladder Cancer Patients
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Dru...
July 14, 2026 | News
Takeda Backs Indonesia's Plasma Ambitions with US$30 Million Investment to Build ASEAN's First Integrated Plasma Ecosystem
Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi...
July 14, 2026 | News
Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...
July 14, 2026 | Analysis
HanchorBio Partners with InxMed to Explore New Combination Strategies for Lead Cancer Therapy
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist I...
July 13, 2026 | News
WuXi Biologics' Hebei Facility Clears US FDA Pre-License Inspection for Commercial Manufacturing
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance ma...
July 13, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
